Dr. Sean Ianchulev and Dr. Pamela Gallin discuss myopia and the positive results from its EYN PG21 proof-of-concept study demonstrating that its micro-dose of latanoprost successfully lowered intraocular pressure (IOP) and achieved patient usability.
Dr. Sean Ianchulev, MD, MPH, Co-Founder, CEO and President of Eyenovia.
Dr. Ianchulev is a Harvard trained physician, eye-surgeon and Professor of Ophthalmology at New York Eye and Ear Infirmary of Mount Sinai. As an innovator and disruptive technology developer, he has been at the core of medical products and technologies which have transformed the ophthalmic field and are impacting medical care for hundreds of thousands of patients every year.
Dr. Ianchulev is a prolific inventor, innovator, pioneer and developer behind some of the most impactful sight-saving technologies and therapies approved by the FDA over the last decade – from Lucentis for Macular degeneration and diabetic retinopathy (Genentech), to intraoperative aberrometry for high-precision cataract surgery (Ora, Alcon), the first suprachorodoial micro-stent for glaucoma (CyPass, Alcon) and the first micro-internvetional technology for cataract surgery (miLOOP, Iantech).
Dr. Ianchulev founded Eyenovia in 2015 to revolutionize the treatment of eye diseases and create the first smart technology for high-precision piezo-print microdosing – a new way to take eye medication.Eyenovia is a clinical stage biopharmaceutical company developing a pipeline of eye care products made possible through a precise topical dosing approach.
Eyenovia makes new therapies possible. Its unique delivery platform uses breakthrough piezo-print technology for high-precision micro-dosing. Micro-dosing allows for fully effective therapies that may also avoid many tolerability and side-effect issues associated with traditional eye drop delivery.
Pamela F. Gallin, MD, FACS
Dr. Pamela F. Gallin is a Clinical Professor of Ophthalmology (in Pediatrics) at New York-Presbyterian – Columbia University Medical Center. She is a member of the Eyenovia Scientific Advisory Board.
Dr. Gallin is one of the highest-ranking female surgeons at NY Presbyterian where she is a Director Emeritus, Pediatric Ophthalmology and Adult Strabismus & Clinical Professor of Ophthalmology in Pediatrics NY Presbyterian-Columbia University Medical Center. She is the author of “Pediatric Ophthalmology”, a textbook used internationally. Dr. Gallin graduated from Washington University in St. Louis MD (Top 10%), AB, BS: Summa Cum Laude, Phi Beta Kappa and Tau Beta Pi (Engineers Phi Beta Kappa). Her Ophthalmology residency at The Mt. Sinai Medical Center (NY) was followed by a Heed Foundation Fellowship. She studied: Pediatric Ophthalmology (Marshall Parks, MD, Children’s National Medical Center and Dr. Philip Knapp, MD Columbia University Medical Center), Pediatric Ophthalmic Oncology (Robert Ellsworth. MD & David Abramson, MD) and Genetics (Irene Maumenee, MD).
Dr. Gallin graduated summa cum laude, Phi Beta Kappa, and Tau Beta Pi (Engineering Phi Beta Kappa) in Engineering from Washington University, St. Louis, where she received her medical degree in the top 5% of her class. Her internship at New York University was followed by a residency at Mt. Sinai Medical Center.